{"id":470240,"date":"2021-04-01T17:35:29","date_gmt":"2021-04-01T21:35:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470240"},"modified":"2021-04-01T17:35:29","modified_gmt":"2021-04-01T21:35:29","slug":"diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/","title":{"rendered":"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, April  01, 2021  (GLOBE NEWSWIRE) &#8212; Diazyme Laboratories, Inc. announced March 30th that it has obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test. The Diazyme test is a high throughput chemiluminescent immunoassay with excellent correlation to a fluorescence based neutralization assay, which has been used to evaluate the adaptive immune response in vaccine studies<sup>1<\/sup>. Diazyme also announced plans to work with US FDA for EUA application.<\/p>\n<p align=\"justify\">\u201cUnlike the widely available total SARS-CoV-2 IgG antibody tests, Diazyme\u2019s neutralizing antibody test measures the subset of neutralizing antibodies that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein and the human ACE2 cell surface receptor. The Diazyme neutralizing antibody test gives the scientific community and health authorities a valuable tool to evaluate the level of effective antibodies generated after infection or vaccination, and to assess adaptive immunity in studies going forward. Diazyme serology tests meet real world expectations from healthcare professionals and have been independently evaluated in several published studies<sup>2<\/sup><sup>&#8211;<\/sup><sup>4<\/sup>,\u201d said Dr. Chong Yuan, Managing Director of Diazyme Laboratories, Inc.<\/p>\n<p>\n        <strong>About Diazyme<\/strong>\n      <\/p>\n<p align=\"justify\">Diazyme Laboratories, Inc., a Life Science Affiliate of General Atomics, is located in Poway, California, USA. Diazyme uses its proprietary enzyme and immunoassay technologies to develop diagnostic test reagents run on automated chemistry analyzers and chemiluminescence instruments in user-friendly formats. Diazyme is a cGMP and ISO 13485 certified medical device manufacturer. Information regarding Diazyme&#8217;s technology and products can be found on its website at\u00a0<a href=\"http:\/\/www.diazyme.com\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.diazyme.com<\/a><\/p>\n<p>\n        <strong>For Further Information Contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Sales\u00a0and Marketing<\/strong><br \/>\n        <br \/>Emile Dergham<br \/><u><a href=\"mailto:sales@diazyme.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">sales@diazyme.com<\/a><\/u><\/p>\n<p>\n        <strong>Regulatory\/Operational<\/strong><br \/>\n        <br \/>Abhijit Datta, Ph.D. <br \/><a href=\"mailto:support@diazyme.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>support@diazyme.com<\/u><\/a><\/p>\n<p>\n        <strong>References<\/strong>\n      <\/p>\n<ol style=\"list-style-type:decimal\">\n<li>\n          <em>E E. Walsh, M.D., R W. Frenck, Jr., M.D., A R. Falsey, M.D., et al., Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, <\/em><br \/>\n          <em>New England Journal of Medicine, 2020; 383:2439-2450<\/em><br \/>\n          <em>, <\/em><br \/>\n          <em><br \/>\n            <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2027906\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2027906<\/a><br \/>\n          <\/em>\n        <\/li>\n<li>\n          <em>R T. Suhandynata, M A. Hoffman, M J. Kelner, <\/em><br \/>\n          <em>et al<\/em><br \/>\n          <em>., Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19,\u00a0<\/em><br \/>\n          <em>The Journal of Applied Laboratory Medicine<\/em><br \/>\n          <em>, Volume 5, Issue 5, September 2020, Pages 908\u2013920,\u00a0<a href=\"https:\/\/doi.org\/10.1093\/jalm\/jfaa079\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/doi.org\/10.1093\/jalm\/jfaa079<\/a><\/em>\n        <\/li>\n<li>\n          <em>R T. Suhandynata, M A. Hoffman, M J. Kelner, <\/em><br \/>\n          <em>et al<\/em><br \/>\n          <em>., Multi-Platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19,\u00a0<\/em><br \/>\n          <em>The Journal of Applied Laboratory Medicine<\/em><br \/>\n          <em>, Volume 5, Issue 6, November 2020, Pages 1324\u20131336,\u00a0<a href=\"https:\/\/doi.org\/10.1093\/jalm\/jfaa139\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/doi.org\/10.1093\/jalm\/jfaa139<\/a><\/em>\n        <\/li>\n<li>\n          <em>R T. Suhandynata, N J. Bevins, J T. Tran, et al., SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses, medRxiv, 2021.03.10.21253299; doi: <\/em><br \/>\n          <em><br \/>\n            <a href=\"https:\/\/doi.org\/10.1101\/2021.03.10.21253299\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/doi.org\/10.1101\/2021.03.10.21253299<\/a><br \/>\n          <\/em>\n        <\/li>\n<\/ol>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/36300228-9420-423a-aeff-a92d3cf65e15\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) &#8212; Diazyme Laboratories, Inc. announced March 30th that it has obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test. The Diazyme test is a high throughput chemiluminescent immunoassay with excellent correlation to a fluorescence based neutralization assay, which has been used to evaluate the adaptive immune response in vaccine studies1. Diazyme also announced plans to work with US FDA for EUA application. \u201cUnlike the widely available total SARS-CoV-2 IgG antibody tests, Diazyme\u2019s neutralizing antibody test measures the subset of neutralizing antibodies that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein and the human ACE2 cell surface receptor. The Diazyme neutralizing antibody test gives the scientific community and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470240","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) &#8212; Diazyme Laboratories, Inc. announced March 30th that it has obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test. The Diazyme test is a high throughput chemiluminescent immunoassay with excellent correlation to a fluorescence based neutralization assay, which has been used to evaluate the adaptive immune response in vaccine studies1. Diazyme also announced plans to work with US FDA for EUA application. \u201cUnlike the widely available total SARS-CoV-2 IgG antibody tests, Diazyme\u2019s neutralizing antibody test measures the subset of neutralizing antibodies that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein and the human ACE2 cell surface receptor. The Diazyme neutralizing antibody test gives the scientific community and &hellip; Continue reading &quot;Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T21:35:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test\",\"datePublished\":\"2021-04-01T21:35:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/\"},\"wordCount\":422,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/\",\"name\":\"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=\",\"datePublished\":\"2021-04-01T21:35:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/","og_locale":"en_US","og_type":"article","og_title":"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test - Market Newsdesk","og_description":"SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) &#8212; Diazyme Laboratories, Inc. announced March 30th that it has obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test. The Diazyme test is a high throughput chemiluminescent immunoassay with excellent correlation to a fluorescence based neutralization assay, which has been used to evaluate the adaptive immune response in vaccine studies1. Diazyme also announced plans to work with US FDA for EUA application. \u201cUnlike the widely available total SARS-CoV-2 IgG antibody tests, Diazyme\u2019s neutralizing antibody test measures the subset of neutralizing antibodies that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein and the human ACE2 cell surface receptor. The Diazyme neutralizing antibody test gives the scientific community and &hellip; Continue reading \"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T21:35:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test","datePublished":"2021-04-01T21:35:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/"},"wordCount":422,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/","name":"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=","datePublished":"2021-04-01T21:35:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3OCM0MDk4OTg0IzIwOTA4NzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diazyme-laboratories-inc-announces-ce-ivd-for-its-semi-quantitative-sars-cov-2-neutralizing-antibody-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470240"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470240\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}